☆ 4.6 Article

Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma

BLOOD ADVANCES (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Letter Hematology

Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma

Andrea Kuhnl et al.

BLOOD ADVANCES (2022)

添加到收藏夹

Article Hematology

Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy

Ajlan Al Zaki et al.

Summary: For patients with large B-cell lymphoma who achieve partial response or stable disease on day 30 PET-CT scan after receiving axicabtagene ciloleucel treatment, about 70% of them will progress. However, the factors that predict this progression are still unknown. A retrospective study at MD Anderson Cancer Center found that platelet count and maximum standardized uptake volume may be associated with disease progression.

BLOOD ADVANCES (2022)

添加到收藏夹

Article Hematology

Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma

Hua-Jay J. Cherng et al.

Summary: IpWGS of cfDNA can be used for risk stratification to identify high-risk patients and guide patient selection and evaluation of targeted therapies in future clinical trials.

BLOOD (2022)

添加到收藏夹

Article Oncology

Rethinking the immunotherapy numbers game

Rebecca A. Bekker et al.

Summary: Immunotherapies have revolutionized oncology by delivering unprecedented response rates in the treatment of certain cancers. However, the reasons for varying responses among patients remain unclear. Understanding the tumor microenvironment and the tumor-immune ecosystem is crucial in predicting treatment outcomes. This article highlights the potential of integrated mathematical oncology approaches in conceptualizing the impact of immunotherapies on tumor response and introducing combination therapies to improve patient outcomes.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Hematology

Assessing CAR T-Cell Therapy Response Using Genome-Wide Sequencing of Cell-Free DNA in Patients With B-Cell Lymphomas

Aaron M. Goodman et al.

Summary: This study aims to demonstrate the feasibility of using cfDNA to predict CAR-T cell therapy response in patients with refractory B-cell lymphomas. The results provide a proof-of-concept for the use of multiple liquid biopsy technologies to monitor therapeutic response in these patients.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

添加到收藏夹

Review Oncology

Circulating Tumor DNA in Lymphoma: Principles and Future Directions

Mark Roschewski et al.

Summary: Lymphomas are heterogeneous tumors with variable outcomes. Current treatment response assessment methods cannot detect disease at the molecular level, and molecular tumor analyses cannot accurately capture spatial tumor heterogeneity. Circulating tumor DNA (ctDNA) is a minimally invasive biomarker that overcomes limitations of imaging scans and tissue biopsies, aiding clinical decision-making in lymphoma.

BLOOD CANCER DISCOVERY (2022)

添加到收藏夹

Article Oncology

Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial

Matthew J. Frank et al.

Summary: This study demonstrated the prognostic value of circulating tumor DNA (ctDNA) in predicting outcomes of large B-cell lymphoma patients undergoing axicabtagene ciloleucel (axi-cel) treatment. Higher baseline ctDNA concentrations were associated with progression post-treatment and development of toxicities. Additionally, patients with undetectable ctDNA 1 week after axi-cel infusion had higher rates of durable response compared to those with detectable ctDNA.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Hematology

High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma

Erin A. Dean et al.

BLOOD ADVANCES (2020)

添加到收藏夹

Article Medicine, General & Internal

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Jeremy S. Abramson et al.

LANCET (2020)

添加到收藏夹

Letter Oncology

Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy

Nasheed M. Hossain et al.

LEUKEMIA & LYMPHOMA (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells

Mohamed-Reda Benmebarek et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

添加到收藏夹

Review Medicine, General & Internal

Cell-free tumour DNA testing for early detection of cancer - a potential future tool

G. Barbany et al.

JOURNAL OF INTERNAL MEDICINE (2019)

添加到收藏夹

Article Oncology

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

Frederick L. Locke et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Hematology

Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy

Bruce D. Cheson et al.

BLOOD (2016)

添加到收藏夹

Review Oncology

Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer

Feifei Cheng et al.

ONCOTARGET (2016)

添加到收藏夹

Article Oncology

Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study

Mark Roschewski et al.

LANCET ONCOLOGY (2015)

添加到收藏夹

Article Oncology

Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography

Michel Meignan et al.

ONCOLOGIST (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

Hidden Markov Models and their Applications in Biological Sequence Analysis

Byung-Jun Yoon

CURRENT GENOMICS (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.